Liposomal Paromomycin
Phase 1Small molecule
Liposomal Paromomycin is one of 31 small molecule programs targeting Cutaneous Leishmaniasis. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Cutaneous Leishmaniasis
#DrugCompanyPhaseTrials
1Levaquin
WWim Janssens
Approved
Garamycin
SSchering-Plough
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Impavido
KKnight Therapeutics (USA) Inc
Phase 3
Meglumine Antimoniate
UUniversity of Brasilia
Approved
Pentam
FFresenius Kabi Oncology Ltd.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Aldara
BBausch Health Americas, Inc.
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Cipro
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Liposomal Paromomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details